Most actions take just a few minutes of your time, but they’re a reminder to policymakers that you have expectations for how they use their influence and vote on policy. If you’re reaching out to a legislator, whether through email or social media, include your connection to lung cancer and why it’s important they take the action you want.
New action items are added often. Join the LUNGevity Action Network to get email alerts when your voice is needed.
Congress is still working to finalize appropriations for fiscal year (FY) 2024, which begins on October 1. They need to hear from you about the importance of lung cancer research funded through the National Institutes of Health, the National Cancer Institute, and the Congressionally Directed Medical Research Programs at the Department of Defense.
Step therapy is a tool used by insurers that requires patients to try a lower-cost prescription drug to treat their condition before “stepping up” to a more expensive option, even if the latter is recommended by the patient’s healthcare provider. In some cases, this leads to poorer health outcomes, more side effects, and ultimately higher costs.
For many people living with cancer, oral chemotherapy is an option that allows for more convenient treatment than intravenous (IV) medicines. However, the way oral drugs are covered by insurance often means much higher copays, making them unaffordable.
The Comprehensive Cancer Survivorship Act, a legislative priority for LUNGevity and the broader cancer community, was recently reintroduced by Reps. Wasserman Schultz (D-FL), Fitzpatrick (R-PA), and DeSaulnier (D-CA) in the House and by Sens. Klobuchar (D-MN) and Cardin (D-MD) in the Senate
Reps. Higgins (D-NY), Fitzpatrick (R-PA), and Castor (D-FL) have reintroduced the Increasing Access to Lung Cancer Screening Act (H.R. 4286), a legislative priority for LUNGevity and the lung cancer community.